Working at Ablynx

Ablynx, a Sanofi company, is a biopharmaceutical company focused on the development of next generation biological medicines based on single-domain antibody fragments, which we have named Nanobodies. Learn more about our Company

Ablynx is setting up its commercial organisation in the different European countries, together with its partner Syneos Health. For more information, please go to: http://germany.commercialcareers.syneoshealth.com/pages/kam-orphan-drug; or contact: Bianca.Melchert@inventivhealth.com or Thomas.Zadro@inventivhealth.com

JOIN OUR TEAM

Further your career by joining the team at Ablynx. Each day you will have the opportunity to contribute and to develop your skills and experience in a young, fast moving and multicultural environment. At Ablynx, we embrace diversity, be it age, gender, ethnicity, nationality, religion, or working and thinking style.

The working environment at Ablynx is innovative, focused and open with a great deal of independence within the job function. You will have the opportunity to work with an outstanding scientific and business team and contribute to the discovery and development of the next novel Nanobody drug. As a company, we strive to provide all our employees with the means to develop their skills and experiences, at any level, and this in an environment and atmosphere where having fun at work is a reality.

Ablynx offers a casual yet dynamic environment, continuous development with competitive salaries and benefits.

We invite you to join our team and to explore our Job Opportunities section to find the positions we are currently recruiting for.

MESSAGE TO RECRUITERS AND HEADHUNTERS

If you believe you can make a contribution, please send us an e-mail with your offer and contact details to the following e-mail address: recruitment@ablynx.com.

Please do not use this e-mail address in case you wish to apply for an open position.

Best wishes,

HR

Awards

Phase III HERCULES results of caplacizumab in aTTP included in the “Best of ASH” session at the 59th ASH Annual Meeting

Phase III HERCULES results of caplacizumab in aTTP included in the “Best of ASH” session at the 59th ASH Annual Meeting